FDA Approves Duavee to Treat Hot Flashes and Prevent Osteoporosis

null

FDA Approves Duavee to Treat Hot Flashes and Prevent Osteoporosis

The U.S. Food and Drug Administration approved Duavee (conjugated estrogens/bazedoxifene). It is a prescription medicine that is used after menopause for women with a uterus to reduce moderate to severe hot flushes and help reduce chances of developing osteoporosis. Duavee is marketed by Wyeth Pharmaceuticals, Inc. (a subsidiary of Pfizer Inc.,) based in Philadelphia, Pa. See  http://www.drugs.com/newdrugs/fda-approves-duavee-hot-flashes-prevent-osteoporosis-3922.html for more information.

Advertisements
This entry was posted in Medication and tagged , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s